Tebipenem pivoxil - Spero Therapeutics
Alternative Names: GSK-3778712; L-084; ME1211; Orapenem; SPR-994; TBP-PI-HBr; TBPM-PI-HBr; Tebipenem; Tebipenem HBr; Tebipenem pivoxil hydrobromide; Tebipenem-prodrugLatest Information Update: 08 Aug 2024
At a glance
- Originator Wyeth K.K.
- Developer GSK; Meiji Seika Pharma; Spero Therapeutics; Wyeth K.K.
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Azabicyclo compounds; Azetidines; Carbapenems; Esters; Small molecules; Thiazoles
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemophilus infections; Streptococcal infections
- Preregistration Pyelonephritis; Urinary tract infections
- Phase II Shigella infections
- No development reported Unspecified
Most Recent Events
- 15 Jul 2024 Spero Therapeutics initiates a Phase-III clinical trials in Pyelonephritis in Estonia (PO) (NCT06059846) (EudraCT2023-503785-22-00)
- 15 Jul 2024 Spero Therapeutics initiates a Phase-III clinical trials in Urinary tract infections (Complicated) in Estonia (PO) (NCT06059846) (EudraCT2023-503785-22-00)
- 09 May 2024 Phase-III clinical trials in Pyelonephritis in Croatia (PO) (NCT06059846)